Progress toward realizing the promise of decentralized clinical trials
- PMID: 38384913
- PMCID: PMC10879994
- DOI: 10.1017/cts.2023.706
Progress toward realizing the promise of decentralized clinical trials
Conflict of interest statement
Dr Lindsell reported receiving grants to the institution from the NCATS for the submitted work; grants to the institution from NIH and Department of Defense and research funds to the institution from the CDC, bioMerieux, AstraZeneca, AbbVie, Entegrion Inc., and Endpoint Health outside the submitted work; patents for risk stratification in sepsis and septic shock issued to Cincinnati Children’s Hospital Medical Center; service on DSMBs unrelated to the current work; and stock options in Bioscape Digital unrelated to the current work. Radha Rajasingham is supported by National Institute of Allergy and Infectious Diseases (K23AI138851). Drs. Rajasingham’s and Boulware’s COVID-19 research has been supported via Rainwater Charitable Foundation, Jan and David Baszucki, the Minnesota Chinese Chamber of Commerce, the Alliance of Minnesota, Chinese Organizations, University of Minnesota Foundation, as well as Dr Boulware’s research supported by ACTIV-6, Parsemus Foundation, Fast Grants, and UnitedHealth Group Foundation.
References
-
- United States Food and Drug Administration. Use of Electronic Informed Consent in Clinical Investigations - Questions and Answers. (https://www.fda.gov/regulatory-information/search-fda-guidance-documents...). Accessed November 30, 2023.
-
- Clinical Trials Transformation Initiative. CTTI Recommendations: Dencentralized Clinical Trials. CTTI Recommendations: Decentralized Clinical Trials. (ctti-clinicaltrials.org). Accessed November 30, 2023.